Research Analysts Set Expectations for Valneva Q4 Earnings

Valneva SE (NASDAQ:VALN) – Stock analysts at HC Wainwright decreased their Q4 2024 EPS estimates for shares of Valneva in a report released on Wednesday, February 19th. HC Wainwright analyst E. White now anticipates that the company will earn ($0.17) per share for the quarter, down from their prior forecast of ($0.15). HC Wainwright has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Valneva’s current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Valneva’s Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.36) EPS, FY2026 earnings at ($1.23) EPS and FY2027 earnings at ($1.28) EPS.

Valneva Price Performance

Shares of VALN opened at $7.44 on Friday. Valneva has a fifty-two week low of $3.62 and a fifty-two week high of $9.50. The firm has a 50-day simple moving average of $5.25 and a 200-day simple moving average of $5.67. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The company has a market capitalization of $604.57 million, a price-to-earnings ratio of -57.23 and a beta of 1.98.

Institutional Trading of Valneva

A number of hedge funds have recently added to or reduced their stakes in the stock. AlphaCentric Advisors LLC lifted its holdings in shares of Valneva by 33.7% during the third quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company’s stock worth $717,000 after purchasing an additional 29,748 shares during the period. ABC Arbitrage SA acquired a new position in shares of Valneva during the fourth quarter worth about $84,000. Finally, Wells Fargo & Company MN raised its holdings in Valneva by 14.3% during the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock worth $1,079,000 after purchasing an additional 30,859 shares in the last quarter. 11.39% of the stock is owned by institutional investors and hedge funds.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.